Oramed Pharmaceuticals (ORMP) vs ProQR Therapeutics N.V. (PRQR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, gaining 38.4% versus a loss of 49.5%. Over five years, ORMP leads with a -82.3% price change compared with -85.5% for PRQR. Oramed Pharmaceuticals is the larger company by market cap ($155.2 million vs $147.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORMP | PRQR |
|---|---|---|
| Share price | $3.57 | $1.04 |
| Market cap | $155.24M | $146.98M |
| 1-day change | -3.25% | -0.95% |
| YTD return | +25.26% | -48.51% |
| 1-year return | +38.37% | -49.51% |
| 5-year return | -82.34% | -85.54% |
| P/E ratio (TTM) | 1.05 | — |
| EPS (TTM) | $3.41 | $-0.43 |
| Dividend yield | 7.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.00M | — |
| Net income (latest FY) | $64.05M | — |
| Gross margin | 0.65% | — |
| Operating margin | -754.40% | — |
| Net margin | 3202.50% | — |
| 52-week high | $5.47 | $2.49 |
| 52-week low | $2.52 | $1.00 |
| Distance from 52-week high | -34.73% | -58.15% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +96.08% | +626.92% |
| Average volume | 173.38K | 793.64K |
| Shares outstanding | 43.49M | 141.33M |
| Employees | — | 186 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed PRQR by 87.9 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (7.00% vs 0.00%).
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
ORMP vs PRQR FAQ
Which is bigger, Oramed Pharmaceuticals or ProQR Therapeutics N.V.?
Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $155.24M compared with $146.98M for ProQR Therapeutics N.V. (PRQR).
Which stock has performed better over the past year, ORMP or PRQR?
ORMP returned +38.37% over the past 12 months, compared with -49.51% for PRQR (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Oramed Pharmaceuticals or ProQR Therapeutics N.V.?
Oramed Pharmaceuticals pays a dividend yielding 7.00%, while ProQR Therapeutics N.V. does not currently pay a regular dividend.
Are Oramed Pharmaceuticals and ProQR Therapeutics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.